Table 5.
Current literature addressing regression in melanoma.
| First Author [citation] | Year | Number of patients | Incidence of Regression (%) | Regression as prognostic factor |
|---|---|---|---|---|
| Guitart [4] | 2002 | 43 | 42% (metastatic) 5% (nonmetastatic) |
Negative prognostic indicator for metastasis |
| Gromet [11] | 1978 | 121 | 19% | Negative prognostic indicator for metastasis |
| Paladugu [12] | 1983 | 36 | 30% | Negative prognostic indicator for metastasis |
| Sondergaard [14] | 1985 | 486 | N/A | Negative prognostic indicator for survival |
| Clark [15] | 1989 | 501 | N/A | Negative prognostic indicator for survival |
| Blessing [16] | 1990 | 26 | 50% | Difference in regression rate b/w metastatic and nonmetastatic thin melanoma |
| Slingluff [13] | 1988 | 681 | 40% (metastatic) 17%(nonmetastatic) |
Negative prognostic indicator for metastasis |
| Wanebo [21] | 1985 | 48 | 50% | Not a prognostic indicator for survival |
| Kelly [18] | 1985 | 844 | 20.4% | Not a prognostic indicator for survival |
| McGovern [19] | 1983 | 353 | 58% | Not a prognostic indicator for survival |
| Trau [20] | 1983 | 116 | 35% | Not a prognostic indicator for metastasis |
| Cooper [17] | 1985 | 48 | 23% definite 27% probable |
Not a prognostic indicator for metastasis |
| Morris [22] | 2008 | 344 | 25.5% | Not a predictor for SLN status or recurrence |
| Cecchi [23] | 2007 | 50 | 70% | Not a predictor for SLN status |
| Socrier [24] | 2010 | 397 | 23% | Not a predictor for SLN status |
| Kramkimel [45] | 2010 | 34 | 76% | Not a predictor for SLN status |
| Kaur [46] | 2008 | 146 | 48% | Not a predictor for SLN status |